EARS unveils AM-111 Phase 3 trial outcomes in a peer-reviewed article
Category: #health  By Paroma Bhattacharya  Date: 2019-03-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

EARS unveils AM-111 Phase 3 trial outcomes in a peer-reviewed article

Auris Medical Holding AG (EARS), a Switzerland-headquartered pharmaceutical company, has reportedly announced the publication of a peer-reviewed scientific article which contains detailed outcomes of the HEALOS Phase 3 trial with AM-111. AM-111 for the record, is the investigational treatment developed by Auris Medical for severe inner ear hearing loss.

Reportedly, the article that discusses the efficacy & safety of AM-111 in the treatment of unilateral sudden deafness in randomized, placebo-controlled Phase 3 study, has been published in one of the leading scientific journals in the field of clinical inner ear research, named Otology & Neurotology.

Hinrich Staecker, PhD, MD, University of Kansas Medical Center, who is also the lead author of the book, was quoted stating that the HEALOS trial shows that the right hearing protection can be possible through a drug-based approach, even in case of acute hearing loss, with poor prognosis for recovery and high risk of cognitive disability. He went on to say that treating with a single dose of AM-111 led to a clinically profound hearing recovery in the trial and marked the signs of improvement and moreover, he affirmed that the outcomes appear to be quite promising.

According to a press release by Auris Medical, the HEALOS trial was conducted in several Asian and European countries and enrolled around 256 patients victimized by severe, sudden deafness. The patients were reportedly randomized in a 1:1:1 ratio for receiving a single dose of AM-111 0.8 mg/mL, AM-111 0.4 mg/mL or placebo, to be administered in the middle ear. However, the trial did not meet the prime efficacy endpoint in the entire study population but, the post-hoc analyses showed significant improvement with AM-111, right from the baseline to Day 28.

For those uninitiated, AM-111 is developed with a biocompatible gel formulation for treating sudden sensorineural hearing loss. It holds an orphan drug designation (ODD) from both the European Medicines Agency (EMA) and US FDA (Food & Drug Administration) and was granted a Fast Track status by the FDA.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

CVS to sell CBD-infused topical products in 800 stores across 8 states
CVS to sell CBD-infused topical products in 800 stores across 8 states
By Paroma Bhattacharya

CVS has partnered with cannabis producers to infuse CBD and sell topical products like roll-ons, lotions, creams, slaves and sprays.

CVS pharmacy has announced that...

Roche’s Tecentriq immunotherapy for SCLC treatment approved by USDFA
Roche’s Tecentriq immunotherapy for SCLC treatment approved by USDFA
By Paroma Bhattacharya

The US FDA (Food & Drug Administration) has reportedly granted approval for Swiss drug-maker Roche Holding’s immunotherapy Tecentriq intended for treating ES-SCLC (Extensive Stage-Small Cell Lung Cancer). Rep...

Tourism Malaysia & ShopBack join hands to lure travelers to the nation
Tourism Malaysia & ShopBack join hands to lure travelers to the nation
By Paroma Bhattacharya

In a move to facilitate growth of online travel bookings, Tourism Malaysia and ShopBack Malaysia have reportedly entered into a collaboration to support the biggest ShopBack-organized Online Travel Fair, being held in ...